NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current immunotherapies, today announced a collaboration and option-to-license agreement to develop multispecific biologics for multiple targets in oncology.

伊利诺伊州北芝加哥和康涅狄格州布兰福德（BRANFORD），2024年10月31日/PRNewswire/--AbbVie（纽约证券交易所：ABBV）和EvolveImmune Therapeutics，一家开发下一代生物治疗药物以克服癌细胞对当前免疫疗法的治疗挑战的免疫肿瘤学公司，今天宣布了一项合作和选择许可协议，以开发用于肿瘤学多个靶标的多特异性生物制剂。

The discovery partnership will leverage EvolveImmune's T-cell engager platform to develop novel antibody-based therapies for solid and hematologic malignancies..

发现合作伙伴关系将利用EvolveImmune的T细胞参与者平台开发针对实体和血液系统恶性肿瘤的新型抗体疗法。。

EvolveImmune's proprietary EVOLVE platform is designed to deliver potent, selective and integrated T-cell co-stimulation to amplify and sustain the tumor killing capacity of the T-cells. This approach aims to bypass low tumor immunogenicity, conditionally activate adaptive immunity and reduce T-cell dysfunction to overcome therapeutic challenges in solid and hematologic tumors..

EvolveImmune专有的EVOLVE平台旨在提供有效，选择性和整合的T细胞共刺激，以扩增和维持T细胞的肿瘤杀伤能力。这种方法旨在绕过低肿瘤免疫原性，有条件地激活适应性免疫并减少T细胞功能障碍，以克服实体瘤和血液肿瘤的治疗挑战。。

'AbbVie is dedicated to advancing the understanding of devastating diseases like cancer and investing in groundbreaking technologies and therapeutic platforms, to deliver novel treatments for patients with high unmet needs,' said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie.

AbbVie高级副总裁兼发现研究全球负责人乔纳森·塞奇威克（JonathonSedgwick）博士说：“AbbVie致力于增进对癌症等毁灭性疾病的理解，并投资于开创性的技术和治疗平台，为需求未得到满足的患者提供新的治疗方法。”。

'We are excited to collaborate with the talented team at EvolveImmune to further advance their novel T-cell engager platform technology.'.

“我们很高兴与EvolveImmune的天才团队合作，进一步推进他们新颖的T细胞参与者平台技术。”。

'This collaboration with AbbVie, a global leader in oncology, offers tremendous validation of the EVOLVE platform and the dedicated and creative work of the EvolveImmune team,' said Stephen Bloch, M.D., chief executive officer of EvolveImmune. 'We believe that EVOLVE, with its differentiated CD2 co-stimulation strategy, represents a potential next-generation, best-in-class T-cell engager platform and that our technology may offer clinically meaningful benefits for patients.'.

EvolveImmune首席执行官斯蒂芬·布洛赫（StephenBloch）医学博士说，与全球肿瘤学领导者艾伯维（AbbVie）的合作，极大地验证了EVOLVE平台以及EvolveImmune团队的敬业和创造性工作我们相信EVOLVE及其分化的CD2共刺激策略代表了潜在的下一代，一流的T细胞参与者平台，我们的技术可能为患者提供临床上有意义的益处。”。

Under terms of the agreement, EvolveImmune will receive $65 million in aggregate upfront fees and equity investment from AbbVie and is eligible for up to $1.4 billion in aggregate option fees and milestones, as well as tiered royalty payments on net sales.

根据协议条款，EvolveImmune将从AbbVie获得6500万美元的预付费和股权投资，并有资格获得高达14亿美元的期权费和里程碑，以及净销售额的分层版税。

About AbbVie

关于AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.

AbbVie的使命是发现并提供创新药物和解决方案，以解决当今严重的健康问题，并应对未来的医疗挑战。我们致力于在几个关键治疗领域（免疫学、肿瘤学、神经科学和眼部护理）以及Allergan美学产品组合中的产品和服务，对人们的生活产生重大影响。

For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube..

有关AbbVie的更多信息，请访问www.AbbVie.com。在LinkedIn、Facebook、Instagram、X（以前的Twitter）和YouTube上关注@AbbVie。。

About AbbVie in Oncology

关于肿瘤学中的AbbVie

At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination.

在艾伯维，我们致力于改变难以治疗的癌症患者的护理标准。我们正在推进一系列血癌和实体瘤癌症类型的动态研究疗法。。

We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and in situ CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines..

我们通过各种有针对性的治疗方式和生物学干预来实现这一目标，包括小分子疗法，抗体-药物偶联物（ADC），基于免疫肿瘤学的疗法，多特异性抗体和原位CAR-T平台。。。

Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines.

今天，我们广泛的肿瘤学组合包括针对各种血液和实体瘤的批准和研究性治疗。我们正在对世界上一些最广泛和最衰弱的癌症进行多项临床试验，评估20多种研究药物。在我们努力对人们的生活产生重大影响的同时，我们致力于探索解决方案，帮助患者获得我们的癌症药物。

About EvolveImmune Therapeutics

关于EvolveImmune Therapeutics

EvolveImmune Therapeutics, Inc. is an immunotherapy platform company developing first-in-category, multifunctional biotherapeutics designed to overcome cancer-driven immunodeficiency in a range of solid tumors and hematological cancers. First-in-human clinical trials are anticipated in 2025. The company is supported by a syndicate of top-tier life science industry investors including Pfizer Ventures, Solasta Ventures, Bristol Myers Squibb, Takeda Ventures, Inc., Yonjin Ventures and Elm Street Ventures..

预计2025年将进行首次人体临床试验。该公司得到了由顶级生命科学行业投资者组成的财团的支持，这些投资者包括辉瑞风险投资公司（Pfizer Ventures）、索拉斯塔风险投资公司（Solasta Ventures）、百时美施贵宝（Bristol-Myers Squibb）、武田风险投资公司（Takeda Ventures，Inc.）、延津风险投资公司（Yonjin Ve。。